BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

2018 Press releases
E-mail Alerts Receive e-mail alerts | RSS Rss feeds
Keyword search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
06/18/18BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML PatientsPrinter Friendly Version
06/13/18BioLineRx to Participate at JMP Securities 2018 Life Sciences ConferencePrinter Friendly Version
05/22/18BioLineRx Reports First Quarter 2018 Financial ResultsPrinter Friendly Version
05/17/18BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML PatientsPrinter Friendly Version
05/17/18BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow TransplantationPrinter Friendly Version
05/16/18BioLineRx to Report First Quarter 2018 Results on May 22, 2018Printer Friendly Version
05/16/18BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid LeukemiaPrinter Friendly Version
03/26/18BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid TumorsPrinter Friendly Version
03/14/18BioLineRx to Present at the 28th Annual Oppenheimer Healthcare ConferencePrinter Friendly Version
03/06/18BioLineRx Reports Year End 2017 Financial ResultsPrinter Friendly Version
02/27/18BioLineRx to Report Annual 2017 Results on March 6, 2018Printer Friendly Version
02/06/18BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13Printer Friendly Version
01/23/18BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cellsPrinter Friendly Version
01/23/18BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical StudiesPrinter Friendly Version
01/17/18BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic CancerPrinter Friendly Version


Interview with Philip Serlin, CEO
December 2016